Peter Attia· MD
Basically, ApoB particles are what matters.
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
Basically, ApoB particles are what matters.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
the more of those particles you have the more of them that are going to end enter the endothelial space the data on this is uh as unambiguous as any data are in medicine from clinical trials epidemiologic trials and mandelian randomization in other words you have the only three layers of evidence you can ever look to experimental data Mr and clinical EPI and they all say the same thing there is a log linear reduction in ascvd as apob goes down